betula verrucosa allergen extract

Allergenexperimental

Clinical trial activity

3 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2007 (NCT00535639)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, desensitized

    Immunity, desensitized

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • betula verrucosa allergen extract

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06085963N/AFeb 1, 2023Karolinska Institute
NCT04912076Phase 1Sep 17, 2018Biomay AG, European Commission, University of Amsterdam, University of Salzburg, University of Southern Denmark
NCT00535639Phase 1Oct 1, 2007ALK-Abello, S.A., PhaseOne Trials
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ALK-Abello, S.A.For profit1112007
Biomay AGFor profit1012018
European CommissionGovernment1012018
Karolinska InstituteAcademic/Hospital1112023
PhaseOne TrialsFor profit1012007
University of AmsterdamAcademic/Hospital1012018
University of SalzburgAcademic/Hospital1012018
University of Southern DenmarkAcademic/Hospital1112018
8 organizations
Page 1 / 1